Due to its higher resolution, oligo array CGH has recently made strong inroads in the cytogenetic lab. It’s not surprising. With an increased sensitivity of more than 1,000-fold, microarrays can ...
Purpose: To develop a high resolution microarray based method to detect single- and multiexons gene deletions and duplications. Methods: We have developed a high-resolution comparative genomic ...
Agilent Technologies Inc. has announced that scientists using an Agilent custom-designed comparative genomic hybridization (CGH) array have sequenced the entire gene map of a Korean male. An ...
Array CGH describes a technology in which microarrays comprised of well-defined DNA probes are used to screen DNA test samples to detect changes in sequence copy number. For whole-genome aCGH, genomic ...
Comparative genomic hybridization (CGH) is used to compare the genetic material from a test individual, such as a leukemia patient, to that of a reference 'normal' individual (usually DNA pooled from ...
Births in Italy and Germany from eggs tested by CGH Two women taking part in the world's first controlled study of a comprehensive genetic screening test before IVF have given birth to healthy babies.
PALO ALTO, Calif., Jan. 5, 2005 -- Agilent Technologies Inc. (NYSE: A) today announced a breakthrough development that enables the rapid advance of microarray-based comparative genomic studies in ...
Purpose: Small supernumerary marker chromosomes are centric chromosomal segments that, by definition, cannot be characterized unambiguously by conventional chromosome banding. Marker chromosomes are ...
Microarray Comparative Genomic Hybridization Reveals Genome-Wide Patterns of DNA Gains and Losses in Post-Chernobyl Thyroid Cancer Robert R. Kimmel, Lue Ping Zhao, Doan Nguyen, Somnit Lee, Mark ...
MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a ...
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...